These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 25085902)

  • 1. Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53.
    Ireno IC; Wiehe RS; Stahl AI; Hampp S; Aydin S; Troester MA; Selivanova G; Wiesmüller L
    Carcinogenesis; 2014 Oct; 35(10):2273-82. PubMed ID: 25085902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
    Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
    Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
    Sizemore ST; Mohammad R; Sizemore GM; Nowsheen S; Yu H; Ostrowski MC; Chakravarti A; Xia F
    Mol Cancer Res; 2018 Jul; 16(7):1092-1102. PubMed ID: 29592899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair.
    Wiltshire TD; Lovejoy CA; Wang T; Xia F; O'Connor MJ; Cortez D
    J Biol Chem; 2010 May; 285(19):14565-71. PubMed ID: 20233726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
    Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M
    Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053
    [No Abstract]   [Full Text] [Related]  

  • 6. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination.
    Schultz N; Lopez E; Saleh-Gohari N; Helleday T
    Nucleic Acids Res; 2003 Sep; 31(17):4959-64. PubMed ID: 12930944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
    Madorsky Rowdo FP; Xiao G; Khramtsova GF; Nguyen J; Martini R; Stonaker B; Boateng R; Oppong JK; Adjei EK; Awuah B; Kyei I; Aitpillah FS; Adinku MO; Ankomah K; Osei-Bonsu EB; Gyan KK; Altorki NK; Cheng E; Ginter PS; Hoda S; Newman L; Elemento O; Olopade OI; Davis MB; Martin ML; Bargonetti J
    Cancer Lett; 2024 Mar; 584():216608. PubMed ID: 38199587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(ADP-ribose) polymerase (PARP-1) and p53 independently function in regulating double-strand break repair in primate cells.
    Süsse S; Scholz CJ; Bürkle A; Wiesmüller L
    Nucleic Acids Res; 2004; 32(2):669-80. PubMed ID: 14757832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
    Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
    Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
    Chao OS; Goodman OB
    Mol Cancer Res; 2014 Dec; 12(12):1755-66. PubMed ID: 25127709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ferulic acid in combination with PARP inhibitor sensitizes breast cancer cells as chemotherapeutic strategy.
    Choi YE; Park E
    Biochem Biophys Res Commun; 2015 Mar; 458(3):520-524. PubMed ID: 25677620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
    Parvin S; Ramirez-Labrada A; Aumann S; Lu X; Weich N; Santiago G; Cortizas EM; Sharabi E; Zhang Y; Sanchez-Garcia I; Gentles AJ; Roberts E; Bilbao-Cortes D; Vega F; Chapman JR; Verdun RE; Lossos IS
    Cancer Cell; 2019 Sep; 36(3):237-249.e6. PubMed ID: 31447348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.
    Cavallo F; Graziani G; Antinozzi C; Feldman DR; Houldsworth J; Bosl GJ; Chaganti RS; Moynahan ME; Jasin M; Barchi M
    PLoS One; 2012; 7(12):e51563. PubMed ID: 23251575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair, and its deficiency sensitizes cells to poly(ADP-ribose) polymerase (PARP) inhibitor treatment.
    Pan MR; Hsieh HJ; Dai H; Hung WC; Li K; Peng G; Lin SY
    J Biol Chem; 2012 Feb; 287(9):6764-72. PubMed ID: 22219182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(ADP-RIBOSE) polymerase-1 (Parp-1) antagonizes topoisomerase I-dependent recombination stimulation by P53.
    Baumann C; Boehden GS; Bürkle A; Wiesmüller L
    Nucleic Acids Res; 2006; 34(3):1036-49. PubMed ID: 16473854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
    Golla RM; Li M; Shen Y; Ji M; Yan Y; Fu K; Greiner TC; McKeithan TW; Chan WC
    Hematol Oncol; 2012 Dec; 30(4):175-9. PubMed ID: 22170260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.
    Bryant HE; Helleday T
    Nucleic Acids Res; 2006; 34(6):1685-91. PubMed ID: 16556909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis.
    Muñoz-Gámez JA; Martín-Oliva D; Aguilar-Quesada R; Cañuelo A; Nuñez MI; Valenzuela MT; Ruiz de Almodóvar JM; De Murcia G; Oliver FJ
    Biochem J; 2005 Feb; 386(Pt 1):119-25. PubMed ID: 15456408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells.
    Tentori L; Portarena I; Bonmassar E; Graziani G
    Cell Death Differ; 2001 May; 8(5):457-69. PubMed ID: 11423906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.